A slew of new studies and reports suggest that new molecular approaches may soon help reduce the global burden of tuberculosis.

"Including bacterial isolates in our FDA studies was a strategic decision — it provides hospital laboratories with flexibility and ensures that QuickMIC integrates seamlessly into existing ...

Roche will receive rights to at least 1 billion lateral flow tests annually from Sapphiros as well as access to the company's future molecular testing technology.